logo-loader
viewClinigen Group PLC

UK regulator licenses two of Clinigen’s short-term jetlag treatments

With marketing authorisations secured, Clinigen’s jetlag drops and tablets can now be prescribed immediately by doctors

businessman with jetlag
The marketing authorisations are further examples of Clinigen’s unlicensed to licensed strategy

Two of Clinigen Group PLC’s (LON:CLIN) jetlag treatments have been granted marketing authorisations by the UK’s medicines regulator.

As the Medicines and Healthcare products Regulatory Agency has now licensed them, the Melatonin drops and tablets can now be prescribed right away. They can also be sold directly to wholesalers.

Previously, the treatments could only be prescribed when doctors had exhausted all other avenues.

READ: Clinigen takes back direct control of two of its oncology drugs in US

Given the likely sales boost from being licensed, Clinigen expects the treatments will be a “modest contributor of growth” within the commercial medicines business this year, offsetting a forecast decline in the unlicensed medicines division.

“This approval will ensure healthcare professionals can manage adult patients experiencing jet-lag with a licensed product, where before there was none,” said chief executive Shaun Chilton.

“Identifying and developing products to offer licensed options to prescribers and patients is an important part of our strategy in Commercial Medicines. We are continuing to explore and invest to further strengthen and diversify the portfolio.”

Havnig opened lower, Clinigen shares were up 1.2% to 1,021p on Wednesday afternoon, valuing the company at £1.3bn.

--Adds share price--

Quick facts: Clinigen Group PLC

Price: 835 GBX

AIM:CLIN
Market: AIM
Market Cap: £1.11 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Clinigen Group PLC named herein, including the promotion by the Company of Clinigen Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Clinigen Group reports on 'transformational' year with strong profit growth

Clinigen Group PLC's (LON:CLIN) head of investor relations Matt Parrish caught up with Proactive London's Andrew Scott following the release of the firm's results for the year to June 2019. The firm's gross profit was up 30% at £182.3mln, while revenues were ahead 20% at £456.9mln. Underlying...

on 19/9/19

2 min read